Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP002 in Advanced Solid Tumors
NCT05982080Phase 1Recruiting
- Sponsor
- Fapon Biopharma
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FP002 in solid tumor (advanced stage), sponsored by Fapon Biopharma. Primary endpoints: Severity of Dose Limiting Toxicity, Severity of treatment-emergent Adverse Events up to 24 months and 3 more. Started Aug 2023; status: recruiting.
02
Drugs
FP002
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05982080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982080.